EGFR and cancer: In this platform, the palmitoylation inhibitor 2-bromopalmitic acid (2-BP) was encapsulated in PLGA nanoparticles to enhance the treatment efficacy of afatinib against EGFR-TKIs non-sensitive cancer cells.